title: Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study.
abstract: OBJECTIVE
  To compare the efficacy of different therapies in the treatment of macular edema associated with retinal vein occlusion (RVO).
  
  
  METHODS
  This is a nonrandomized, multicenter collaborative study.
  
  
  METHODS
  86 retina specialists from 29 countries provided clinical information, including choice of treatment and outcome, on 2,603 patients with macular edema including 738 cases of RVO.
  
  
  METHODS
  Reported data included the type and number of treatments performed, visual acuities, and other clinical and diagnostic findings.
  
  
  METHODS
  The mean increase in visual acuity and mean number of treatments performed.
  
  
  RESULTS
  358 cases of central retinal vein occlusion (CRVO) and 380 cases of branch retinal vein occlusion (BRVO) were included in this investigation. Taking all RVO cases together, pars plana vitrectomy with internal limiting membrane (ILM) peeling alone resulted in an improvement in vision greater than other therapies. Those treated with intravitreal antivascular endothelial growth factor (anti-VEGF) injection alone showed the second greatest improvement in vision. Dexamethasone intravitreal implant alone and intravitreal triamcinolone alone both resulted in modest visual gains.
  
  
  CONCLUSIONS
  In the treatment of macular edema in RVO, vitrectomy with ILM peeling may achieve visual improvement and may be a good option for certain cases. Anti-VEGF injection is the most effective of the nonsurgical treatments.
authors.affiliation: Yale Eye Center, 40 Temple Street No. 3d, New Haven, CT 06510, USA.
authors.forename: Ron A
authors.initials: RA
authors.lastname: Adelman
authors.affiliation: Eyecare Medical Group, 53 Sewall Street, Portland, ME 04102, USA.
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Parnes
authors.affiliation: Augenklinik Universitätsallee Bremen GmbH, Parkallee 301/Universitätsallee, 28213 Bremen, Germany.
authors.forename: Silvia
authors.initials: S
authors.lastname: Bopp
authors.affiliation: Cairo University, Cairo University Road, Oula, Giza, Egypt.
authors.forename: Ihab
authors.initials: I
authors.lastname: Saad Othman
authors.affiliation: European VitreoRetinal Society, 8 rue Camille Flammarion, 44000 Nantes, France.
authors.forename: Didier
authors.initials: D
authors.lastname: Ducournau
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000473:pathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects*; D014821:Vitrectomy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D014221:Triamcinolone; D000068258:Bevacizumab; D003907:Dexamethasone